NCT03857321View on ClinicalTrials.gov

Study of Nasal Insulin to Fight Forgetfulness - Device Study

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 12, 2019

Primary Completion Date

September 27, 2019

Study Completion Date

September 30, 2019

Conditions
Mild Cognitive ImpairmentCognitive Impairment
Interventions
DRUG

Insulin

20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly \& Company)

OTHER

Placebo

Matching placebo (sterile saline) to 20 IU Humulin® R U-100

DEVICE

intranasal nebulizer-like device

Participants will be assigned to receive placebo or regular insulin (U100, 20 IU) administered through an intranasal nebulizer-like device.

Trial Locations (1)

27157

Wake Forest University Health Sciences, Winston-Salem

All Listed Sponsors
lead

Wake Forest University Health Sciences

OTHER

NCT03857321 - Study of Nasal Insulin to Fight Forgetfulness - Device Study | Biotech Hunter | Biotech Hunter